NCT01018095

Trichomonas Vaginalis Recurrence Among HIV+ Women

Randomized Phase IV Trial of Metronidazole Single Dose Versus 7 Day Dose for Treatment of Trichomonas Vaginalis Among HIV-infected Women

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 270 (actual)
• Sponsor: Tulane University Health Sciences Center · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if the 2 gram single dose of metronidazole is as effective as the 7 day 500 mg BID dose for treatment of Trichomonas vaginalis (TV) among HIV-infected women.

Detailed description

This is a Phase IV equivalency trial as both doses of metronidazole are listed in the the Centers for Disease Control and Prevention Treatment Guidelines for the treatment of T vaginalis.

Conditions

• Trichomonas Infections
• HIV Infections

Interventions

Type	Name	Description
DRUG	Metronidazole	2 gm single dose versus 7 day 500 mg BID dose

Timeline

• Start date: 2005-05-01
• Primary completion: 2009-07-01
• Completion: 2009-08-01
• First posted: 2009-11-23
• Last updated: 2016-12-20
• Results posted: 2013-07-15

Locations

5 sites across 1 country: United States